ClinicalTrials.gg
CompletedNCT04224545COCSUpdated Feb 20, 2024

COlchicine in Cardiac Surgery

A Phase 4 interventional study of Colchicine Pill and Placebo in Colchicine Adverse Reaction and Atrial Fibrillation New Onset, sponsored by Bakulev Scientific Center of Cardiovascular Surgery. Completed at 2 sites in Russian Federation. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2024-02-20.

Sponsored by Bakulev Scientific Center of Cardiovascular Surgery · Phase 4, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
267
Allocation
Randomized
Ages
40 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 22 studies testing colchicine in Atrial Fibrillation — 4 open to participants now, 5 under way, 3 of them phase 3. Colchicine · Atrial Fibrillation.

Enrollment
8th of 22
267 · median 236
Started
2019
with 2 others
Phase 4
4 of 22
1 open now
Registered
12th of 22
by date
Lead sponsor
1 of 22
Bakulev Scientific Center of Cardiovascular Surgery

Among the 22 studies testing colchicine in Atrial Fibrillation, this one is the 8th largest by enrollment, is one of 3 that started in 2019, is one of 4 in phase 4, and was the 12th registered.

Atrial Fibrillation

4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

4 of the 22 studies testing colchicine in Atrial Fibrillation are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About colchicine

Colchicine: first FDA approval 1961 (COLBENEMID), first EMA approval 2026. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: 40 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies testing colchicine in Atrial Fibrillation, or all of them as a file.
02

Study summary

Postoperative atrial fibrillation (POAF) is a major complication of cardiac surgery, which could lead to high morbidity and mortality, increase duration of hospital stay and increase the cost of treatment. Colchicine possesses both anti-inflammatory and sympatholytic properties, so it has been studied to prevent POAF. The ACC/AHA guidelines for colchicine contain a class IIB recommendation, but the ESC guidelines do not recommend this drug. More researches are needed to focus on reducing of side effects by optimizing the colchicine regimen to reduce the incidence of gastrointestinal side effects. It is believed that further research is needed to investigate the efficacy and safety of colchicine in these conditions.

This research is aimed to study the effectiveness of short-term administration of the drug.

Read the detailed description

Postoperative atrial fibrillation (POAF) is a major complication of cardiac surgery, which could lead to high morbidity and mortality, increase duration of hospital stay and increase the cost of treatment. Postoperative AF is considered as a multifactorial phenomenon. Its pathogenesis is characterized by inflammation, oxidative stress and autonomic dysfunction. Several predisposing factors lead to the development of POAF, including pre -, intra-and postoperative factors. The main of them are age, previous history of major cardiovascular risk factors and ischemic reperfusion injury during surgery. Treatment of POAF involves drugs to control the frequency of rhythm in hemodynamically stable patients and other treatment regimens usually used for the treatment of AF. Intraoperative administration of beta-blockers and some antiarrhythmic drugs is recommended by international clinical guidelines. In addition, previous treatment consisting of the use of colchicine, magnesium sulfate, statins and antioxidants have reduced the incidence of postoperative AF. However, the results of large-scale randomized trials have observed the development of undesirable adverse reactions.

Despite these recommendations, the question of the correct regimen for prevention of POAF remains controversial. Colchicine possesses both anti-inflammatory and sympatholytic properties, so it has been studied to prevent POAF. The ACC/AHA guidelines for colchicine contain a class IIB recommendation, but the ESC guidelines do not recommend this drug.

Two studies sequentially COPPS-1 and COPPS-2 evaluated the effect of colchicine on the incidence of POAF after open heart surgery (COPPS-1) and the development of postcardiotomy syndrome (COPPS-2). In COPPS-1, patients (n=336) were treated with colchicine from the third day after surgery for a month and showed a significant decrease of POAF after heart surgery over the entire follow-up period. 360 patients were evaluated in the COPPS-2 study. The incidence of POAF between the colchicine and placebo groups was comparable, although colchicine significantly reduced postpericardiotomy syndrome. The main limitation of the COPSS-2 study was the high rate of cessation of intervention (20% of participants), which had a significant impact on the outcome of the trial.

Based on the latest meta-analysis of the colchicine effect on POAF after heart surgery, it was found that it still reduces POAF compared with control (HR = 0.69, 95% IM 0.57-0.84, p = 0.0002) and the duration of hospital stay was reduced by 1.2 days (95% IM -1.89 to -0.44, p = 0.002); however, the frequency of adverse gastrointestinal events increased significantly (HR = 2.52, 95% IM 1.62-3.93, p \< 0.0001). Despite the high level of side effects, a significant reduction of POAF outweighs the balance in the favor of its use. However, more researches are needed to focus on reducing of side effects by optimizing the colchicine regimen to reduce the incidence of gastrointestinal side effects. It is believed that further research is needed to investigate the efficacy and safety of colchicine in these conditions.

This research is aimed to study the effectiveness of short-term administration of the drug.

03

Conditions studied

  • Colchicine Adverse Reaction
  • Atrial Fibrillation New Onset

Browse trials for

Keywords

  • Colchicine
  • Postoperative atrial fibrillation
  • Anti-inflammatory
  • Cardiac surgery
  • Sympatholytic
04

Who can participate

Ages eligible
40 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Adult patients awaiting elective cardiac surgery (CABG and/or AVR (aortic valve replacement), who are willing and able to give for participation in the study and who are in sinus rhythm and not taking any antiarrhythmic medication, except beta-adrenergic blocking agents, at the time before surgery.

Exclusion criteria

Exclusion Criteria:

  • History of persistent or long-term atrial fibrillation/atrial flutter
  • Congenital heart disease, except the bicuspid AV
  • Frequent VE/SVE, AV block 2-3 degrees
  • Use of during the last month
  • Taking any antiarrhythmic drugs, except beta-blockers, within the last 1 month
  • Prior "open" heart surgery
  • Moderate to severe renal failure ( \< 50 ml / min)
  • History of obstructive hepato-biliary disease or other serious hepatic disease
  • Significant mitral valve disease (moderate or severe mitral regurgitation-eg. > grade II and/or mitral stenosis \& mitral annular calcification).
  • Patient participation in another clinical trial
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
267 participants (actual)

Study arms

  • Experimental
    Colchicine

    Colchicine 1 mg day (COLCHICINA LIRCA ® ACARPIA Farmaceutici S.r.l.)

    Drug: Colchicine Pill

  • Placebo comparator
    Placebo

    Sugar pill

    Drug: Placebo

Interventions

  • DrugColchicineStudies of ColchicineColchicine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Colchicine at a dose of 1 mg a day before surgery, 2, 3, 4, 5 days after surgery.

    Also known as: group C

  • DrugPlacebo

    Placebo started a day before surgery, 2, 3, 4, 5 days after surgery.

    Also known as: group P

06

What researchers measure

Primary outcomes

  1. Number of participants with postoperative atrial fibrillation.

    POAF detected on continuous ECG monitoring.

    Time frame: Monitoring is carried out immediately after surgery and will be continued until the end of the 7th postoperative day.

Secondary outcomes

  1. Number of participants with lethal and non-lethal events.

    The main nosocomial lethal and non-lethal events (death, stroke, myocardial infarction, heart failure).

    Time frame: Participants will be followed for the duration of the postoperative period up to the day of initial discharge from the hospital, an expected average of 7 days.

  2. Fluid in the pericardium.

    Fluid in the pericardium evaluated by echocardiography.

    Time frame: Diagnostics will be carried out on the 3rd and 5th day after surgery.

  3. Fluid in the pleura.

    Fluid in the pleura evaluated by echocardiography.

    Time frame: Diagnostics will be carried out on the 3rd and 5th day after surgery.

  4. Acute kidney damage (according to the dynamics of creatinine clearance).

    Dynamics of creatinine clearance.

    Time frame: Diagnostics will be carried out a day before surgery and on the 3rd and 5th day after surgery.

  5. Inflammation in blood plasma.

    Dynamics of biomarker of inflammation in blood plasma (neutrophils).

    Time frame: Diagnostics will be carried out a day before surgery and on the 3rd and 5th day after surgery.

  6. Liver damage

    Dynamics of biomarkers of liver damage (aspartate aminotransferase, alanine aminotransferase).

    Time frame: Diagnostics will be carried out a day before surgery and on the 3rd and 5th day after surgery.

07

Study locations

2 sites
  • Federal Center for Cardiovascular Surgery (Astrakhan)
    Astrakhan, Russian Federation
  • Bakulev National Medical Research Center for Cardiovascular Surgery
    Moscow, Russian Federation
08

References and documents

Publications

  • Shvartz V, Le T, Kryukov Y, Sokolskaya M, Ispiryan A, Khugaeva E, Yurkulieva G, Shvartz E, Petrosyan A, Bockeria L, Bockeria O. Colchicine for Prevention of Atrial Fibrillation after Cardiac Surgery in the Early Postoperative Period. J Clin Med. 2022 Mar 3;11(5):1387. doi: 10.3390/jcm11051387. PubMed 35268478 ↗
  • Shvartz V, Le T, Enginoev S, Sokolskaya M, Ispiryan A, Shvartz E, Nudel D, Araslanova N, Petrosyan A, Donakanyan S, Chernov I, Bockeria L, Golukhova E. Colchicine in Cardiac Surgery: The COCS Randomized Clinical Trial. J Cardiovasc Dev Dis. 2022 Oct 20;9(10):363. doi: 10.3390/jcdd9100363. PubMed 36286314 ↗
  • Shvartz V.A., Le T.G., Enginoev S.T., Sokolskaya M.A., Ispiryan A.Yu., Shvartz E.N., Nudel D.V., Araslanova N.Kh., Petrosyan A.D., Talibova S.M., Donakanyan S.A., Chernov I.I., Boсkeria L.A., Golukhova E.Z. Association of new markers of systemic inflammation with the risk of developing for the first time postoperative atrial fibrillation when using colchicine in patients undergoing open heart surgery. Annals of arrhythmology. 2023; 20(1): 22-33. (In Russian).

Individual participant data

Plan to share: Yes — The datasets analyzed during the current study are publicly available. The data is available in the general repository "Open Science Framework" at the link

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: until 2045

Access criteria: open access

Data sharing details ↗ · doi.org

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2019 to primary completion in Aug 2022, 31 months.

Of 130 non-industry phase 4 interventional studies under Atrial Fibrillation, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 81. This study's 31 months is below that.

Counting every sponsor, half of 142 studies reached it within 48 months; a quarter within 27 and three quarters within 81.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 27, 2019
First posted
Jan 13, 2020
StartActual
Dec 23, 2019
Primary completionActual
Aug 15, 2022
CompletionActual
Aug 23, 2022
Last update
Feb 20, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 20, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04224545
Lead sponsor
Bakulev Scientific Center of Cardiovascular Surgery
Responsible party
Sponsor
First posted
Jan 13, 2020
Start date
Dec 23, 2019
Primary completion
Aug 15, 2022
Completion
Aug 23, 2022
Last update
Feb 20, 2024

Study contacts

Vladimir Shvartz
principal investigator · Bakulev National Medical Research Center for Cardiovascular Surgery

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Colchicine

Start the discussion